A venture capital firm with multiple offices throughout US and outside of US invests in several areas of technology including biotech, medical devices and digital health. The firm participates in venture and growth investments as well as buyouts – allocations can range from $5-200m. The firm is open to global opportunities.
Within the healthcare sector, the firm is highly interested in healthcare IT and also has some interest in medical devices and diagnostics. For devices and diagnostics, the firm has a strong preference for investing in products that have already achieved FDA clearance; only exceptional pre-clearance products will be considered and in those cases, the firm will only look at 510k products that are very close to approval; PMAs will not be considered. The firm is open to all indication areas, and has experience and expertise in diabetes, ENT, metabolic diseases, and the spine; the firm generally does not invest in highly invasive medical devices. The firm may also consider opportunities in laboratory tools and analytical drug discovery tools (but not drug discovery service models). In recent, the firm has expanded their investment areas into biotech and life sciences, and is open to investing across all modalities and indications in both pre-clinical and clinical stage assets.
The firm invests in privately-held companies, and prefers to back experienced management teams with previous entrepreneurial successes. The firm prefers to invest in companies with over $2 million in revenue (over $3 million for healthcare IT companies), and with a customer base that includes large hospital networks or high-profile customers. Defensible IP is also a highly important factor.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment